Harborside


Khiron Life Sciences Corp.

CVE: KHRN


Canadian symbol: KHRN.V
US symbol: KHRNF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 38.51M
Enterprise Value 25.02M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.81
Price/Book (mrq)0.70
Enterprise Value/Revenue 2.14
Enterprise Value/EBITDA -1.63

Trading Information

Stock Price History

Beta (5Y Monthly) 1.93
52-Week Change 3-53.66%
S&P500 52-Week Change 322.93%
52 Week High 30.7600
52 Week Low 30.1900
50-Day Moving Average 30.2542
200-Day Moving Average 30.3892

Share Statistics

Avg Vol (3 month) 3175k
Avg Vol (10 day) 3239.09k
Shares Outstanding 5179.12M
Implied Shares Outstanding 6N/A
Float 8169.95M
% Held by Insiders 14.77%
% Held by Institutions 11.59%
Shares Short (Nov. 14, 2021) 4214.73k
Short Ratio (Nov. 14, 2021) 41.18
Short % of Float (Nov. 14, 2021) 4N/A
Short % of Shares Outstanding (Nov. 14, 2021) 40.12%
Shares Short (prior month Oct. 14, 2021) 4228.52k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3May 23, 2018
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Sep. 29, 2021

Profitability

Profit Margin -137.04%
Operating Margin (ttm)-144.60%

Management Effectiveness

Return on Assets (ttm)-16.57%
Return on Equity (ttm)-30.14%

Income Statement

Revenue (ttm)11.68M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)82.50%
Gross Profit (ttm)7.01M
EBITDA -16.22M
Net Income Avi to Common (ttm)-16M
Diluted EPS (ttm)-0.1060
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)15.42M
Total Cash Per Share (mrq)0.09
Total Debt (mrq)1.93M
Total Debt/Equity (mrq)3.52
Current Ratio (mrq)4.94
Book Value Per Share (mrq)0.31

Cash Flow Statement

Operating Cash Flow (ttm)-20.98M
Levered Free Cash Flow (ttm)-13.73M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
KHRN.V
Khiron Life Sciences
1 week ago
KHRN.V
Khiron Life Sciences
1 week ago
KHRN.V
Khiron Life Sciences
2 weeks ago
KHRN.V
Khiron Life Sciences
2 weeks ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
12 months ago
KHRN.V
Khiron Life Sciences
12 months ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago
KHRN.V
Khiron Life Sciences
2 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts0002
Avg. Estimate000-0.16
Low Estimate000-0.2
High Estimate000-0.13
Year Ago EPS-0.11-0.09N/AN/A
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1112
Avg. Estimate1.9M2.8M8.02M14.35M
Low Estimate1.9M2.8M7.6M13.1M
High Estimate1.9M2.8M7.6M15.6M
Year Ago Sales2.21M2.77M9.58M8.02M
Sales Growth (year/est)-13.90%1.00%-16.30%79.00%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.09-0.08-0.09-0.09
EPS Actual-0.11-0.09-0.06-0.08
Difference-0.02-0.010.030.01
Surprise %-22.20%-12.50%33.30%11.10%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate000-0.16
7 Days Ago-0.07-0.05-0.24-0.16
30 Days Ago-0.07-0.05-0.24-0.16
60 Days Ago-0.07-0.05-0.24-0.16
90 Days Ago-0.07-0.05-0.24-0.16
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/A1N/AN/A
Up Last 30 DaysN/A1N/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesKHRN.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
4.77%% of Shares Held by All Insider
1.59%% of Shares Held by Institutions
1.67%% of Float Held by Institutions
5Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
AdvisorShares Investments, LLC639,337Sep. 29, 20210.36%175,817

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF619,930Oct. 30, 20210.35%158,082
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Khiron Life Sciences Corp.


Khiron Announces Grants of Options and Restricted Share Units

Khiron Announces Grants of Options and Restricted Share Units

TORONTO, Nov. 23, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of stock options ("Options") and restricted share units ("RSUs") under the Company's amended and restated restricted s... Read More...
Khiron Reports Q3 Results - Revenue Increased 83% YoY, 26% QoQ

Khiron Reports Q3 Results – Revenue Increased 83% YoY, 26% QoQ

Q3 2021 revenue increased 83% YoY to $3.5 million compared to the previous year Gross profit before changes in FV in Q3 2021 increased 62% sequentially to $1.7 million Medical cannabis revenues increased 46% sequentially to $1.2 million Continued strong gross margins for medical cannabis segment at 89% TORONTO, Nov. 22, 2021 - Khiro... Read More...
Khiron to Host Third Quarter 2021 Conference Call on November 22, 2021

Khiron to Host Third Quarter 2021 Conference Call on November 22, 2021

TORONTO, Nov. 16, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, November 22nd , 2021 at 10:00 a.m. Eastern Time to discuss its resul... Read More...
Khiron Life Sciences to Present at Upcoming November Investor Conferences

Khiron Life Sciences to Present at Upcoming November Investor Conferences

TORONTO, Nov. 8, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is scheduled to participate in the following virtual and in-person conferences in November 2021: CANNABIS EUROPABanking Hall, LondonNovember ... Read More...
Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

Zerenia™ Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic (www.zereniaclinic.co.uk) and will also offer in-person appointments with medical cannabis specialist pra... Read More...
Khiron reports medical cannabis prescription growth in South America and Europe

Khiron reports medical cannabis prescription growth in South America and Europe

TORONTO, Oct. 4, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on global medical cannabis operations: Medical Cannabis Latin America Medical cannab... Read More...
Khiron's Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO

Khiron’s Announces Resignation of Chief Financial Officer Swapan Kakumanu of RTB LLP appointed as Interim CFO

TORONTO, Oct. 1, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announced that Joel Friedman, has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's board of d... Read More...
Khiron Announces Intention to Renew its Normal Course Issuer Bid

Khiron Announces Intention to Renew its Normal Course Issuer Bid

TORONTO, Sept. 9, 2021 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF) , (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Ex... Read More...
Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide

Khiron Registers its First Two Medical Cannabis Products in Peru, Available for Sale Nationwide

Currently in Peru, the Company sells magistral preparations, or customized compound formulations, through its exclusive agreement with Farmacia Universal. In contrast, as shelf-ready medical cannabis products, Alixen™ 30™ and Alixen™ 100 will be made widely available, on a non-exclusive basis in the country.  Alixen™ 30 will target indic... Read More...
Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

Q2 2021 revenues of $2.8 million, up 68% YoY Medical cannabis revenues reach $825,500, up 47% sequentially, with sales in Colombia, Germany, UK, and Peru contributing to gross medical cannabis profit margin of 88% European medical cannabis sales growth of 280% sequentially, representing over 25% of total medical cannabis revenues Medi... Read More...
Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021

Khiron to Host Second Quarter 2021 Conference Call on August 23, 2021

TORONTO, Aug. 17, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Monday, August 23rd , 2021 at 10:00 a.m. Eastern Time to discuss its results... Read More...
Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership

Khiron Publishes Inaugural 2020 ESG Report, Demonstrating Commitment to Sustainability and Continued Market Leadership

"At Khiron, sustainability is embedded in our DNA, with the common belief that strong ESG policies improve performance, loyalty, and innovation, while reducing corporate risks and capital costs. Our inaugural ESG report demonstrates our dedication to strong environmental, social and governance principles as we deliver on our Mission of im... Read More...
Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis

Colombia Expands Distribution of Medical Cannabis to Pharmacies Nationwide and Opens Export Market for Dried Flower Medical Cannabis

On July 23, 2021, the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal insurance coverage... Read More...
Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court's Advancement of Cannabis Laws

Vicente Fox, Khiron Board Member and Former President of Mexico, Applauds Mexican Supreme Court’s Advancement of Cannabis Laws

Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy Recent regulatory and supply chain advances accelerate... Read More...
Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia

Khiron Accelerates Entry into Mexico, Awarded High-THC Extract Export Quotas for Mexico by the Government of Colombia

With a population close to 130 million people, Mexico is among the top 15 economies worldwide and second largest in Latin America. Approximately 11.7 million people have conditions treatable with medical cannabis (Source: IMS Quintiles) Leveraging its Project of National Strategic Interest (PINES) designation, Khiron receives THC extrac... Read More...
Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

Khiron Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

Khiron launches first Zerenia medical cannabis clinic, via a strategic partnership with Lima-based Clinica Montesur Tweet this Alvaro Torres, CEO and Director comments, "I am pleased to announce the first expansion of our Zerenia brand beyond Colombia. Knowing that prescription rates at our Zerenia clinics are 14 times higher than th... Read More...
Khiron Announces Upcoming Investor Events and Grant of Options and Restricted Share Units

Khiron Announces Upcoming Investor Events and Grant of Options and Restricted Share Units

TORONTO, May 31, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company´s management will be participating in the following investor: Jefferies Healthcare Confere... Read More...
Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations

Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations

Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations Tweet this Alvaro Torres, CEO and Director comments, "We are very excited to be partnering with some of the country's leading specialized medical institutions to increase awareness and provide safe access to patients seeking different ... Read More...
Khiron to Host First Quarter 2021 Conference Call on May 28, 2021

Khiron to Host First Quarter 2021 Conference Call on May 28, 2021

Khiron to Host First Quarter 2021 Conference Call on May 28, 2021 Tweet this Webcast Details:DATE: May 28th, 2021TIME: 10:00am ET/7:00am PT/4:00pm CETPRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Joel Friedman, Khiron Chief Financial Officer, and Chris Naprawa, Chairman of Khiron Board of DirectorsFORMAT: Liv... Read More...
Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education

Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK’s Cellen Therapeutics to Improve Clinician Education

Khiron has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK Tweet this Tejinder Virk, President of Khiron Europe, commented, "Over the last year, Khiron has seen a direct correlation between physician education and patient access. With Khiron Academy's CPD accreditation and throug... Read More...
Khiron Medical Cannabis Products Arrive in Germany for Immediate Prescription, Sale and Distribution

Khiron Medical Cannabis Products Arrive in Germany for Immediate Prescription, Sale and Distribution

First shipment of Khiron branded EU-GMP certified medical cannabis to Germany successfully completed, providing immediate access to German market through distribution partner, Nimbus Health GmbH Launch product is Khiron 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and migraines, addressi... Read More...
Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2

Khiron Updates Zerenia™ Expansion Program; Announces Plans to Open Three Additional Satellite Clinics in Colombia by End of Q2

"We are off to a great start in 2021 and the Zerenia satellite clinic model is proving to be an exceptional platform for reaching new patients. The rapid expansion of clinics is helping Khiron reach more patients in more places, more conveniently, in these cities. With the opening of two new satellite clinics in Cali and Bucaramanga, Khir... Read More...
Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe

Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe

Tejinder Virk, President of Khiron Europe, commented: "Our experience in Colombia and Europe tells us that doctors require solid clinical evidence to feel confident that medical cannabis is the right treatment for their patients. By exporting our Colombian cannabis strains, we will be able to bring our Latin American extracts to European ... Read More...
Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America

Khiron and Tecnologico de Monterrey of Mexico Launch First Internationally Accredited Medical Cannabis Diploma in Latin America

International Diploma in Medicinal Cannabis for Latin American doctors to be hosted virtually through Mexico's TecSalud School of Medicine and Health Sciences (EMCS), beginning February 20, 2021 Physicians from Mexico and across Latin America will participate in a fee-based 6-week diploma program Diploma marks a historic advance in med... Read More...
Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch

Khiron Announces Expansion of Small-Format Zerenia™ Clinics in Colombia Following Success of Initial Launch

Khiron to launch two additional small-format Zerenia™ clinics in major metropolitan centres outside of Bogota in early March 2021, following successful launch of the Company's first small-format clinic in Medellin in December 2020 New clinics bring Khiron's total number of clinics in Colombia to six, expanding regional access throughout... Read More...
Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference

Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference

TORONTO, Jan. 8, 2021 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will participate live at the ATB 9th Annual Institutional Investor Conf... Read More...
article placeholder

Khiron to Present at the 13th Annual LD Micro Main Event Conference

TORONTO, Dec. 11, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on December 14th. Khiron Chairman ... Read More...
Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia

Khiron Becomes First Company to Export High THC Medical Cannabis From Colombia

Khiron High THC medical cannabis product successfully imported into Peru, with first prescriptions to be filled in December through a partnership with Farmacia Universal S.A.C. Khiron is the first company to export High THC medical cannabis from Colombia, and the only Colombian company authorized to fill High THC prescriptions in Peru f... Read More...
Khiron Life Sciences Corp Invites You to Join Us at the Benzinga Global Small Cap Conference

Khiron Life Sciences Corp Invites You to Join Us at the Benzinga Global Small Cap Conference

Toronto, Ontario--(Newsfile Corp. - December 7, 2020) - Khiron Life Sciences Corp (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2020. We invite our shareholders and all inter... Read More...
Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Khiron Medical Cannabis Products Now Qualify for National Insurance Coverage in Colombia

Khiron applauds Colombia on becoming one of the first countries to extend national health insurance for patients to include medical cannabis as a first line therapy Leveraging Khiron's status as a National Strategic Project, Khiron medical cannabis products and clinic services are now covered by health insurance companies in Colombia O... Read More...
Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia

Khiron to Open New Regional Zerenia™ Clinic in Medellin, Colombia

The Medellin clinic, with a grand opening planned for December 8, 2020, supports Khiron´s goal of expanding regional access to the Company's proven clinic services and medical cannabis products for patients across the country, with a focus on in-person and telehealth services in Colombia's largest urban centres. The clinic is convenientl... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
KHRN.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.19CAD-13.64%
4KH.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.14EUR-5.26%
KHRNF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.15USD-14.60%
KHRN.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.19CAD-13.64%
4KH.BE
Berlin Stock Exchange
Berlin Stock Exchange0.13EUR-10.77%
4KH.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange0.14EUR-0.99%
4KH.MU
Munich Stock Exchange
Munich Stock Exchange0.15EUR0.00%
4KH.H
Hamburg Stock Exchange
Hamburg Stock Exchange0.15EUR+0.68%
4KH.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.13EUR-10.14%
KHRN.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.21CAD0.00%

Delayed data (1h)
NameAgePositionAppointed
Chris Naprawa
Chairman of the Board
--Chairman of the Board2020
Alvaro Torres
Chief Executive Officer, Director
40Chief Executive Officer, Director2018
Swapan Kakumanu
Interim Chief Financial Officer
--Interim Chief Financial Officer2021
Franziska Katterbach
President, Khiron Europe
--President, Khiron Europe2021
Tejinder Virk
President Khiron Europe
--President Khiron Europe2019
Deborah E. Rosati
Lead Independent Director
57Lead Independent Director2020
Juan Carlos Carlos Echeverry Garzon
Independent Director
58Independent Director2020
Vicente Fox Quesada
Independent Director
76Independent Director2020
Alvaro Yanez
Independent Director
41Independent Director2018


Share this page